JEJulie L. Engers

Julie L. Engers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julie L. Engers has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    De Novo Design in an M1 Positive Allosteric Modulator Backup Program: The Discovery of VU6069863

    by Changho Han, Upendra Rathnayake, Alison R. Gregro, Julie L. Engers, Christopher C. Presley, Nathan D. Schley, Analisa D. Thompson Gray, Michael Bubser, Hyekyung P. Cho, Alice L. Rodriguez, et al.

    Recently, we disclosed our M1 PAM that had advanced into Phase I clinical studies, VU0467319, as well as a deuterated back-up compound, VU6045422, to address a major metabolite produced in man and improve tox profile. Ultimately, this series failed to overcome its liabilities and was terminated. However, the team was challenged with developing chemically distinct backup candidates without performing a new HTS campaign. De novo design strategies based upon the other two M1 ago-PAMs that had previously entered clinical development, MK-7622 and TAK-071, led to the discovery of a fundamentally new chemotype based on a 3,4-dihydrobenzo[f][1,4]oxazepin-5-(2H)-one core, providing VU6069863. VU6069863 proved to be an M1 PAM (EC50 = 248 nM, 87% ACh Max) with minimal M1 agonism, (EC50 > 30 μM, 19% ACh Max) despite being derived from potent M1 ago-PAM chemotypes, with good CNS penetration (rat Kp = 0.59, Kp,uu = 0.13, MDCK-MDR1 ER = 1.8, Papp = 32.8 × 10–6 cm/s) and pro-cognitive efficacy in both contextual fear conditioning (minimally effective dose [MED] = 0.1 mg/kg PO) and novel object recognition (MED = 1 mg/kg PO) in rats.

  • Open Access

    Discovery of VU6083859, a TAOK1 Selective Inhibitor, and VU6080195, a pan -TAOK Activator

    by Daniel C. Schultz, Lauren C. Parr, Hunter Sweet, Sean Lamb, Julie L. Engers, Nathaniel C. Napier, Hallie G. McKinnie, David Whomble, Valerie Kramlinger, Olivier Boutaud, et al.

    The thousand and one (TAO) kinases, TAOK1, TAOK2, and TAOK3, have garnered great interest for their role in, and therapeutic potential for, breast cancer, neurodegeneration in human tauopathies, and a large number of neurodevelopmental disorders (NDDs). However, only one pan-TAO kinase inhibitor, referred to as compound 43, has been employed to pharmacologically validate this important family of kinases despite a poor pharmacokinetic(PK) profile and off-target liabilities. In order to understand the isoenzyme-specific role of TAOKs in NDDs and in regulating tau pathology, isoenzyme-selective inhibitors and activators are required. Here, we report on an iterative medicinal chemistry exercise to expand the chemical space around compound 43, which resulted in the first TAOK1 selective inhibitor VU6083859 (TAOK1 IC50 = 158 nM; TAOK2/TAOK1 = 22; TAOK3/TAOK1 > 63; selective versus the Cerep 360 kinase panel) and quite unexpectedly, by virtue of a 'magic methyl,' a pan-TAOK activator, VU6080195 (TAOK1 EC50 = 270 nM, TAOK2 EC50 = 1,376 nM, TAOK3 EC50 = 503 nM; note: the des-methyl congener is a TAOK1-preferring inhibitor). Both new kinase ligands showed modest rat PK, central nervous system (CNS) penetration (Kps > 0.15) and therefore provide a foundation to further optimize this chemotype to probe and validate the role(s) of TAO kinase modulation in the CNS.


  • Open Access

    Discovery of VU6052254: A Novel, Potent M 1 Positive Allosteric Modulator

    by Julie L. Engers, Joseph D. Bungard, Christopher C. Presley, Irene Zagol-Ikapitte, Katherine J. Watson, Sichen Chang, Colin O’cArroll, P. Markus Dey, Ethan S. Burstein, Jonathan W. Dickerson, et al.

    We recently disclosed VU0467319, a muscarinic acetylcholine receptor subtype 1 (M1) Positive Allosteric Modulator (PAM) clinical candidate that had successfully completed a Phase I Single Ascending Dose (SAD) clinical trial, but the identification of an inactive metabolite constituting a major portion of the total plasma AUC detracted from the molecules' pharmacokinetic profile and contributed to clinical development discontinuation. Attempts to block metabolism with the incorporation of deuterium atoms proved successful in vitro and in vivo at low exposures; however, in high-dose nonclinical toxicology studies, the degree of oxidative metabolism and metabolite accumulation was comparable to that of the proteo-congener. Here, we describe a second-generation back-up effort based on the VU0467319 scaffold to discover VU6052254. Strategic placement of a tertiary hydroxyl moiety afforded VU6052254, a potent M1 PAM (EC50 = 59 nM, 79% ACh max), with high CNS exposure (rat Kp = 1.07; Kp,uu = 1.27; P-gp ER = 1.97, Papp = 23 × 10-6 cm/s), reduced metabolism across species, excellent pharmacodynamic responses (MED in rat NOR = 1 mg/kg PO; MED in rat CFC = 0.3 mg/kg PO), excellent multispecies PK (Clps < 10 mL/min/kg, %F > 65), and favorable human PK and dose projections. Based on these beneficial attributes, VU6052254 was nominated for further nonclinical development. However, possible CYP450 induction liability as well as uncertain projected margins for human efficacy at those systemic concentrations where dose/exposure-related clinical and anatomic pathology kidney findings were observed in a 14-day exploratory toxicity study in male rats, precluded further development.

  • Open Access

    Discovery of a Novel sp3-Rich M1 Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping

    by Joseph D. Bungard, Paul Spearing, Yu Nishio, Upendra Rathnayake, Chris C. Presley, Sichen Chang, Haley E. Kling, Analisa D. Thompson, Hyekyung P. Cho, Li Peng, et al.

    The M1 receptor has long been investigated as a promising CNS drug target, yet further research is essential to fully elucidate compound's Pharmacodynamic (PD) as well as Toxicokinetic (TK) effects. In this context, the development of structurally diverse and high-profile M1 PAM tool compounds remains highly valuable, as existing advanced tools exhibit notable structural similarity. One approach that can be considered during scaffold hopping exercise and can improve drug-like properties is to introduce additional sp3 carbon atoms and increase Fsp3 values; the fraction of sp3 hybridized carbons. Determining the correct location to incorporate sp3 carbon atoms can be challenging, but once the right position is identified, it often leads to novel optimization opportunities. Reported herein is the discovery of a novel sp3-rich M1 positive allosteric modulator series utilizing a N-cyclopentyl pyrazole core. Also, an iterative library synthesis approach provided an enhanced understanding of the minimum pharmacophore. Several compounds within the series showed favorable on-target potencies and DMPK properties. In conclusion, the reported sp3-rich N-cyclopentyl pyrazole-based M1 PAM scaffold offers a promising structure-activity relationship starting point to discover structurally distinct M1 PAM chemotypes.


  • Open Access

    Discovery of Pre-Clinical Candidate VU6008055/AF98943: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy

    by Julie L. Engers, Sean R. Bollinger, Alison R. Gregro, Rory A. Capstick, Paul K. Spearing, Madeline F. Long, James C. Tarr, Katherine J. Watson, Sichen Chang, Vincent B. Luscombe, et al.

    Herein, we report the structure-activity relationship to develop novel tricyclic M4 positive allosteric modulator scaffolds with improved pharmacological properties. This endeavor involved modifying a 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide core via a "tie-back" strategy to discover a novel tricyclic 3,4-dimethylpyrimido[4',5':4,5]thieno[2,3-c]pyridazine core. From this exercise, VU6008055/AF98943 was identified as a preclinical candidate, which displays low nanomolar potency against both human and rat M4. Moreover, VU6008055 is highly brain penetrant, has an overall superior pharmacological and DMPK profile to previously reported M4 PAMs, and demonstrates efficacy in preclinical models of antipsychotic-like activity.


  • Open Access

    Discovery of Thieno[3,2-b]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5

    by Katherine E. Crocker, Scott H. Henderson, Rory A. Capstick, David L. Whomble, Aaron M. Bender, Andrew S. Felts, Changho Han, Julie L. Engers, Natasha B. Billard, Mallory A. Maurer, et al.

    This Letter describes the discovery of novel mGlu5 NAMs VU6031545 and VU6024945. Starting from previously reported picolinamide compounds, a structure-activity relationship study of various core isosteres was conducted, leading to the identification of thieno[3,2-b]pyridine-5-carboxamide and 2,3-difluorobenzamide as competent core replacements. These compounds are highly potent as well as brain penetrant with an IVIVC agreement and improved oral bioavailability in rats.


  • Open Access

    Total Synthesis and Pharmacological Evaluation of Phochrodines A–C

    by Jacob L. Bouchard, Sichen Chang, Srinivasan Krishnan, Christopher C. Presley, Olivier Boutaud, Nathan D. Schley, Darren W. Engers, Julie L. Engers, Craig W. Lindsley, Aaron M. Bender

    The first syntheses of the Phomopsis-isolated natural products phochrodines A-C are reported. Functional group manipulations on a key 5H-chromeno[4,3-b]pyridine intermediate, itself synthesized from intramolecular Suzuki-Miyaura coupling, enabled facile and high-yielding syntheses of all three natural products. Additionally, sufficient material was generated to enable detailed pharmacological profiling of each compound. Preliminary drug metabolism and pharmacokinetic (DMPK) experiments and ancillary pharmacology screening revealed phochrodine C (3) as an attractive scaffold for further modification, particularly for medicinal chemists working in the antidepressant space.


  • Open Access

    Application of Deuterium in an M1 Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422

    by Julie L. Engers, Jinming Li, Changho Han, Madeline F. Long, Alison R. Gregro, Christopher C. Presley, Jonathan W. Dickerson, Weimin Peng, Hyekyung P. Cho, Alice L. Rodriguez, et al.

    Recently, we disclosed VU0467319, an M1 positive allosteric modulator (PAM) clinical candidate that had successfully completed a phase I single ascending dose clinical trial. Pharmacokinetic assessment revealed that, in humans upon increasing dose, a circulating, inactive metabolite constituted a major portion of the total drug-related area under the curve (AUC). One approach the team employed to reduce inactive metabolite formation in the back-up program was the kinetic isotope effect, replacing the metabolically labile C-H bonds with shorter, more stable C-D bonds. The C-D dipole afforded VU6045422, a more potent M1 PAM (human EC50 = 192 nM, 80% ACh Max) than its proteocongener VU0467319 (human EC50 = 492 nM, 71% ACh Max), and retained the desired profile of minimal M1 agonism. Overall, the profile of VU6045422 supported advancement, as did greater in vitro metabolic stability in both microsomes and hepatocytes than did VU0467319. In both rat and dog in vivo, low doses proved to mirror the in vitro profile; however, at higher doses in 14-day exploratory toxicology studies, the amount of the same undesired metabolite derived from VU6045422 was equivalent to that produced from VU0467319. This unexpected IVIVC result, coupled with less than dose-proportional increases in exposure and no improvement in solubility, led to discontinuation of VU0467319/VU6045422 development.


  • Open Access

    Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials

    by Michael S. Poslunsey, Michael R. Wood, Changho Han, Shaun R. Stauffer, Joseph D. Panarese, Bruce J. Melancon, Julie L. Engers, Jonathan W. Dickerson, Weimin Peng, Meredith J. Noetzel, et al.

    Herein we detail the first disclosure of VU0467319 (VU319), an M1 Positive Allosteric Modulator (PAM) clinical candidate that successfully completed a Phase I Single Ascending Dose (SAD) clinical trial. VU319 (16) is a moderately potent M1 PAM (M1 PAM EC50 = 492 nM ± 2.9 nM, 71.3 ± 9.9% ACh Max), with minimal M1 agonism (EC50 > 30 μM), that displayed high CNS penetration (Kps > 0.67 and Kp,uus > 0.9) and multispecies pharmacokinetics permissive of further development. Based on robust efficacy in multiple preclinical models of cognition, an ancillary pharmacology profile devoid of appreciable off-target activities, and a lack of cholinergic adverse effects (AEs) in rats, dogs and nonhuman primates, VU319 advanced into IND-enabling studies. After completing 4-week rat and dog GLP toxicology without AEs, including absence of cholinergic effects, the first in human Phase I SAD clinical trial of VU319 (NCT03220295) was performed at Vanderbilt, where a similar lack of adverse effects, including absence of cholinergic effects was noted. Moreover, signals of target engagement were seen at the highest dose tested. Thus, VU319 demonstrated the feasibility of achieving selective targeting of central M1 muscarinic receptors without eliciting cholinergic AEs that have plagued other drugs targeting CNS cholinergic neurotransmission.


  • Open Access

    Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)

    by Julie L. Engers, Logan A. Baker, Sichen Chang, Vincent B. Luscombe, Alice L. Rodriguez, Colleen M. Niswender, Hyekyung P. Cho, Michael Bubser, Analisa Thompson Gray, Carrie K. Jones, et al.

    Herein, we report structure-activity relationship (SAR) studies to develop novel tricyclic M4 PAM scaffolds with improved pharmacological properties. This endeavor involved a "tie-back" strategy to replace a 5-amino-2,4-dimethylthieno[2,3-d]pyrimidine-6-carboxamide core, which led to the discovery of two novel tricyclic cores. While both tricyclic cores displayed low nanomolar potency against both human and rat M4 and were highly brain-penetrant, the 2,4-dimethylpyrido[4',3':4,5]thieno[2,3-d]pyrimidine tricycle core provided lead compound, VU6016235, with an overall superior pharmacological and drug metabolism and pharmacokinetics (DMPK) profile, as well as efficacy in a preclinical antipsychotic animal model.